Abstract
The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has currently spread worldwide, leading to high morbidity and mortality. As the putative receptor of SARS-CoV-2, angiotensin-converting enzyme 2 (ACE2) is widely distributed in various tissues and organs of the human body. Simultaneously, ACE2 acts as the physiological counterbalance of ACE providing homeostatic regulation of circulating angiotensin II levels. Given that some ACE2 variants are known to cause an increase in the ligand-receptor affinity, their roles in acquisition, progression and severity of COVID-19 disease have aroused widespread concerns. Therefore, we summarized the latest literature and explored how ACE2 variants and epigenetic factors influence an individual's susceptibility to SARS-CoV-2 infection and disease outcome in aspects of ethnicity, gender and age. Meanwhile, the possible mechanisms for these phenomena were discussed. Notably, recombinant human ACE2 and ACE2-derived peptides may have special benefits for combating SARS-CoV-2 variants and further studies are warranted to confirm their effects in later stages of the disease process. As the uncertainty regarding the severity and transmissibility of disease rises, a more in-depth understanding of the host genetics and functional characteristics of ACE2 variants will not only help explain individual clinical differences of the disease, but also contribute to providing effective measures to develop solutions and manage future outbreaks of SARS-CoV-2.
Introduction: The Molecular Doorway
While the global impact of COVID-19 is well-documented, the massive variance in clinical outcomes remains a central puzzle. Some individuals are asymptomatic, while others face fatal respiratory failure. The answer lies partly in the host's genetics, specifically the Angiotensin-converting enzyme 2 (ACE2). As the obligate receptor for the SARS-CoV-2 spike protein, any change in the ACE2 protein's structure or expression level could theoretically alter how easily the virus enters cells.
Population Genetics and Variant Affinity
Not all ACE2 receptors are created equal. Genetic "typos" known as Single Nucleotide Polymorphisms (SNPs) can alter the binding affinity between the virus's Receptor Binding Domain (RBD) and the human receptor. Analysis of genomic databases like gnomAD reveals that certain variants are more prevalent in specific ethnic groups. For instance, the K26R variant, which appears to increase the "stickiness" of the receptor for the spike protein, is more common in European populations. Conversely, variants like E35K, more common in East Asians, may offer relative resistance by decreasing affinity.
The Role of Gender and Age
The ACE2 gene is located on the X chromosome, providing women (XX) with a potential "mosaic" expression advantage. Furthermore, ACE2 is known to escape X-inactivation, meaning women may have a higher pool of soluble ACE2 that acts as a natural decoy, protecting against the severe inflammatory "Ang II escape" often seen in men (XY).
Age also plays a critical role through epigenetic regulation. Children often exhibit hypermethylated (silenced) ACE2 genes in their lungs, contributing to their relative resilience. In contrast, the elderly often face hypomethylation—leading to higher ACE2 expression—compounded by zinc deficiencies that impair the regulation of ACE2 by SIRT1.
Therapeutic Potential: Soluble ACE2 as a Decoy
A promising therapeutic strategy involves the use of human recombinant soluble ACE2 (hrsACE2). By flooding the system with these "loose" receptors, the virus binds to the decoys instead of the receptors on cell membranes. In engineered human organoids, hrsACE2 has been shown to reduce viral growth by a factor of 1,000–5,000. To improve clinical viability, researchers have fused rACE2 with an Fc fragment, successfully increasing its plasma half-life from 1.8 hours to over 174 hours.
Conclusion and Future Directions
While ACE2 polymorphisms provide a compelling explanation for individual and population-level differences in COVID-19 severity, challenges remain. Computational models of binding affinity often conflict, and the role of ACE2 in the late-stage cytokine storms of ARDS requires further clarification. Future research must focus on large-scale sequencing of patients with extreme clinical phenotypes to identify rare but high-impact genetic markers, ultimately refining our ability to manage future outbreaks.
Summary updated